TRX - TISSUE REGENIX GROUP - Share Chat
Tissue Regenix Group is a UK-based medical technology company specialising in the development and commercialisation of regenerative medical products. Its core proprietary dCELL® technology decellularises human and animal tissues, removing cellular material to create an acellular scaffold that facilitates natural tissue repair and regeneration.
The company’s primary product is DermaPure®, an acellular dermal matrix widely used in advanced wound care, particularly for chronic wounds like diabetic foot ulcers and venous leg ulcers, addressing a significant unmet medical need. Beyond wound care, Tissue Regenix also applies its technology to dental and soft tissue repair applications. Operating within the dynamic regenerative medicine sector, the company focuses on commercial expansion and increasing market penetration for its innovative biological solutions, aiming to enhance patient outcomes globally.
Chat about TISSUE REGENIX GROUP
Morning all! What's the sentiment on Tissue Regenix (TRX)? Their latest results pointed to strong revenue growth and a clear path to profitability. Are you bullish on their dCELL® technology and market position, or do challenges remain? Keen to hear your views!